Bicycle Therapeutics plc has released a corporate presentation detailing its innovative approach to developing a new class of medicines using Bicycle® molecules. These novel synthetic peptides have the potential to deliver any payload to any target, offering a unique platform based on Nobel Prize-winning science. The company's focus remains on oncology, with expedited development paths for treatments such as zelenectide pevedotin in metastatic urothelial carcinoma. The presentation also highlights a radiopharmaceuticals pipeline targeting novel cancer markers. Bicycle Therapeutics is extending its platform into areas like radiopharmaceuticals and neurology through validating partnerships. The company, with locations in Cambridge, UK, and Cambridge, MA, is listed on NASDAQ under the symbol BCYC and reported cash and cash equivalents of $793.0 million as of March 31, 2025. You can access the full presentation through the link below.